The impact of comorbidities on interleukin-17 inhibitor therapy in psoriatic arthritis: a Danish population-based cohort study

Magnus B Petersen; Rebekka L Hansen; Alexander Egeberg; Tanja S Jørgensen; Joseph Frank Merola; Laura C Coates; Lars Erik Kristensen

doi:10.1093/rap/rkad035

The impact of comorbidities on interleukin-17 inhibitor therapy in psoriatic arthritis: a Danish population-based cohort study

Magnus B Petersen^*, Rebekka L Hansen, Alexander Egeberg, Tanja S Jørgensen, Joseph Frank Merola, Laura C Coates, Lars Erik Kristensen

^*Corresponding author af dette arbejde

2 Citationer (Scopus)

Abstract

OBJECTIVE: To investigate the influence of comorbidities on treatment response, disease activity and persistence with first-line IL-17 inhibitor (IL-17i) treatment in patients with PsA.

METHODS: Patients were divided into three groups depending on the presence and/or severity of comorbidities using the Charlson Comorbidity Index (CCI). Groups were CCI 0: no comorbidities, CCI 1: one comorbidity and CCI ≥2: two or more comorbidities or one or more severe comorbidities. Outcomes in the groups were compared for treatment persistence, treatment response and disease activity.

RESULTS: A higher CCI score was associated to an elevation in baseline CRP, swollen joint count and frequency of depression and/or anxiety. The median drug persistence in the groups were CCI 0: 1.8 years, CCI 1: 1.9 years and CCI ≥2: 1.5 years, but was not statistically significant to the CCI score. There were no significant differences in clinical response rates between the groups.

CONCLUSION: The presence of comorbidities was associated with increased baseline disease activity and frequency of depression and/or anxiety, but was not associated with shorter treatment persistence or lower clinical response rates in a cohort of 155 Danish patients with PsA treated with first-line IL-17i.

Originalsprog	Engelsk
Artikelnummer	rkad035
Tidsskrift	Rheumatology Advances in Practice
Vol/bind	7
Udgave nummer	2
ISSN	2514-1775
DOI	https://doi.org/10.1093/rap/rkad035
Status	Udgivet - 2023

Adgang til dokumentet

10.1093/rap/rkad035

Andre filer og links

Link to publication in Scopus

Citationsformater

@article{13e2475f885d4b56ab7161dd26c03a6b,

title = "The impact of comorbidities on interleukin-17 inhibitor therapy in psoriatic arthritis: a Danish population-based cohort study",

abstract = "OBJECTIVE: To investigate the influence of comorbidities on treatment response, disease activity and persistence with first-line IL-17 inhibitor (IL-17i) treatment in patients with PsA.METHODS: Patients were divided into three groups depending on the presence and/or severity of comorbidities using the Charlson Comorbidity Index (CCI). Groups were CCI 0: no comorbidities, CCI 1: one comorbidity and CCI ≥2: two or more comorbidities or one or more severe comorbidities. Outcomes in the groups were compared for treatment persistence, treatment response and disease activity.RESULTS: A higher CCI score was associated to an elevation in baseline CRP, swollen joint count and frequency of depression and/or anxiety. The median drug persistence in the groups were CCI 0: 1.8 years, CCI 1: 1.9 years and CCI ≥2: 1.5 years, but was not statistically significant to the CCI score. There were no significant differences in clinical response rates between the groups.CONCLUSION: The presence of comorbidities was associated with increased baseline disease activity and frequency of depression and/or anxiety, but was not associated with shorter treatment persistence or lower clinical response rates in a cohort of 155 Danish patients with PsA treated with first-line IL-17i.",

author = "Petersen, {Magnus B} and Hansen, {Rebekka L} and Alexander Egeberg and J{\o}rgensen, {Tanja S} and Merola, {Joseph Frank} and Coates, {Laura C} and Kristensen, {Lars Erik}",

note = "{\textcopyright} The Author(s) 2023. Published by Oxford University Press on behalf of the British Society for Rheumatology.",

year = "2023",

doi = "10.1093/rap/rkad035",

language = "English",

volume = "7",

journal = "Rheumatology Advances in Practice",

issn = "2514-1775",

publisher = "Oxford University Press",

number = "2",

}

TY - JOUR

T1 - The impact of comorbidities on interleukin-17 inhibitor therapy in psoriatic arthritis

T2 - a Danish population-based cohort study

AU - Petersen, Magnus B

AU - Hansen, Rebekka L

AU - Egeberg, Alexander

AU - Jørgensen, Tanja S

AU - Merola, Joseph Frank

AU - Coates, Laura C

AU - Kristensen, Lars Erik

PY - 2023

Y1 - 2023

N2 - OBJECTIVE: To investigate the influence of comorbidities on treatment response, disease activity and persistence with first-line IL-17 inhibitor (IL-17i) treatment in patients with PsA.METHODS: Patients were divided into three groups depending on the presence and/or severity of comorbidities using the Charlson Comorbidity Index (CCI). Groups were CCI 0: no comorbidities, CCI 1: one comorbidity and CCI ≥2: two or more comorbidities or one or more severe comorbidities. Outcomes in the groups were compared for treatment persistence, treatment response and disease activity.RESULTS: A higher CCI score was associated to an elevation in baseline CRP, swollen joint count and frequency of depression and/or anxiety. The median drug persistence in the groups were CCI 0: 1.8 years, CCI 1: 1.9 years and CCI ≥2: 1.5 years, but was not statistically significant to the CCI score. There were no significant differences in clinical response rates between the groups.CONCLUSION: The presence of comorbidities was associated with increased baseline disease activity and frequency of depression and/or anxiety, but was not associated with shorter treatment persistence or lower clinical response rates in a cohort of 155 Danish patients with PsA treated with first-line IL-17i.

AB - OBJECTIVE: To investigate the influence of comorbidities on treatment response, disease activity and persistence with first-line IL-17 inhibitor (IL-17i) treatment in patients with PsA.METHODS: Patients were divided into three groups depending on the presence and/or severity of comorbidities using the Charlson Comorbidity Index (CCI). Groups were CCI 0: no comorbidities, CCI 1: one comorbidity and CCI ≥2: two or more comorbidities or one or more severe comorbidities. Outcomes in the groups were compared for treatment persistence, treatment response and disease activity.RESULTS: A higher CCI score was associated to an elevation in baseline CRP, swollen joint count and frequency of depression and/or anxiety. The median drug persistence in the groups were CCI 0: 1.8 years, CCI 1: 1.9 years and CCI ≥2: 1.5 years, but was not statistically significant to the CCI score. There were no significant differences in clinical response rates between the groups.CONCLUSION: The presence of comorbidities was associated with increased baseline disease activity and frequency of depression and/or anxiety, but was not associated with shorter treatment persistence or lower clinical response rates in a cohort of 155 Danish patients with PsA treated with first-line IL-17i.

UR - http://www.scopus.com/inward/record.url?scp=85160658666&partnerID=8YFLogxK

U2 - 10.1093/rap/rkad035

DO - 10.1093/rap/rkad035

M3 - Journal article

C2 - 37091296

SN - 2514-1775

VL - 7

JO - Rheumatology Advances in Practice

JF - Rheumatology Advances in Practice

IS - 2

M1 - rkad035

ER -

The impact of comorbidities on interleukin-17 inhibitor therapy in psoriatic arthritis: a Danish population-based cohort study

Abstract

Adgang til dokumentet

Andre filer og links

Fingeraftryk

Citationsformater